10 November 2015
1 min read
Statement on NICE Interim Unituxin Decision
As you may have heard, last week the National Institute for Health and Care Excellence (NICE) released a statement to say they are considering not approving the drug Unituxin (dinutuximab) for high-risk neuroblastoma patients.
2 November 2015
1 min read
NICE Consultation
As you may already be aware the NICE (National Institute for Health and Care Excellence) recently published interim guidance that dinutuximab (Unituxin, ch14.18/SP2/0) in combination with GM-CSF and IL-2 is not recommended for use on the NHS.
